Promising results for new RA drug

A new drug for rheumatoid arthritis (RA) could offer a further treatment option for many people living with the condition.

Tocilizumab has shown to significantly slow down symptoms of RA in almost half of the people in a trial, when used alongside existing treatment, methotrexate.

As a result, people with RA who were using the drug experienced reduced joint damage together with reduced pain and improved mobility. There is even some evidence that it can lead to a kind of remission, meaning some people on the trial were experiencing no symptoms at all.

With many decisions about drugs available on the NHS going against people with arthritis, it is hoped that this will offer an effective new option for people who have not responded to other treatments.

Rachel Haynes, Arthritis Care’s director of public affairs said: "The hundreds of thousands of people with rheumatoid arthritis are owed a full part in society but over time they’ve received many body-blows in accessing treatment. Arthritis Care hopes this drug fulfils its promise and everyone who needs it will get early and full access to potentially life-changing benefits, regardless of who they are or where they live".

 Tocilizumab is currently awaiting its license for use in the US and Europe.